Why the study?
Does celecoxib improve health outcomes and reduce costs compared to available alternatives in patients with osteoarthritis and rheumatoid arthritis in Sweden?
Does celecoxib improve health outcomes and reduce costs compared to available alternatives in patients with osteoarthritis and rheumatoid arthritis in Sweden?
Based on a pharmacoeconomic model, the use of celecoxib in Sweden is expected to provide societal benefits by improving health care at reduced cost for patients with OA and RA.
May support Swedish OA/RA prescribing decisions; leaves open need for real-world confirmation before practice change.
The Arthritis Cost Consequence Evaluation System (ACCES) pharmacoeconomic model was used to evaluate the economic and health impact of the recent introduction of celecoxib for treatment of osteoarthritis (OA) and rheumatoid arthritis (RA) in Sweden. The model demonstrates that use of celecoxib can be expected to reduce the incidence of gastrointestinal adverse events, resource utilization and treatment costs. In a cost-effectiveness analysis, celecoxib demonstrated economic dominance (i.e. improved health at reduced cost) compared with the currently available alternatives for OA, and demonstrated economic dominance against a clinically relevant base-case scenario for RA. In sensitivity analyses, the results were shown to be relatively robust; celecoxib demonstrated economic dominance or favourable cost-effectiveness ratios in all analyses. Based on these data, it can be concluded that the use of celecoxib in Sweden will provide societal benefits by improving health care at reduced cost for patients with OA and RA.
No takes yet. Share an insight, caveat, or question.
Haglund et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: